Global Ophthalmic Drugs Market Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388021
  • Report
  • Region: Global
  • 198 pages
  • Mordor Intelligence
1 of 4

Ophthalmic drugs and device market is expected to grow at an exponential rate in the coming years due to the impact in prevalence of eye disease and an increased growth in the percentage of the cataract population. The above developments have resulted in an increase in the production of new ophthalmic devices which in turn has caught the attention of the people. People are increasingly willing to opt for ophthalmic surgeries so that their eye disorders get treated effectively.

The Global Ophthalmology Drugs and Devices Market is expected to become a $40 billion market by 2015 and is expected to grow at a CAGR of 6.1% from 2010-2015. The global ophthalmic drugs market was valued as a $17.3 billion industry in 2013. This industry is expected to grow at a CAGR of 5.4% and is set to become a $22.5 billion industry by 2018.

The Global markets for Ophthalmic drugs and devices are basically segmented into three categories. The segmentations are done on the basis of different drugs used in the treatment of eye disorders. These included drugs for Glaucoma, infections and inflammations.

The major drivers for this market are the availability of new drugs and devices, huge demographic shift towards the emerging markets and the increase in the cataract population. The major constraints being expensive procedures, economic slowdown in developed markets.

The market is again divided on the basis of geography. In the global market US has the largest market share. In the European sector UK has the major share. Recent developments and analysis show that the emerging markets are rapidly rising due to the increase in the cataract population and are expected to show stiff competition against the major players like USA and UK.

The major companies with a share in this market are Abbott Laboratories, Novartis, Pfizer, Bausch & Lomb, Johnson & Johnson, Merck & Co, Inc., Roche Diagnostics,etc.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

1. INTRODUCTION
1.1 Report Description
1.2 Research Methodology
1.3 Stakeholders
2. EXECUTIVE SUMMARY
2.1 Key Findings
2.2 Market Overview
3. MARKET OVERVIEW
3.1 Market Defenition
3.1.1 Introduction
3.2 Market Segmentation
3.2.1 Opthalmic Diseases
3.2.2 Opthalmic Drugs
3.2.3 Opthalmic Devices
3.3 Market Drivers
3.3.1 Demographic shift and impact of prevalence of eye disease
3.3.2 Availability of new drugs and devices
3.3.3 Growth in Cataract Volume
3.4 Market Constraints
3.4.1 Increasing Healthcare costs
3.4.2 Economic Slowdown in developed markets
4. GLOBAL MARKETS: SEGEMENTATION BY TYPE OF DRUGS
4.1 Anti Glaucoma Drugs
4.2 Opthalmic Infection Drugs
4.3 Opthalmic Inflammation Durgs
4.4 Opthalmic Lubricants
4.5 Mydriasis Drugs
4.6 Opthalmic Swelling
5. GLOBAL MARKETS: SEGMENTATION BY GEOGRAPHY
5.1 North America
5.1.1 US
5.1.2 Canada
5.2 Europe
5.2.1 UK
5.2.2 Germany
5.2.3 France
5.3 APAC
5.3.1 India
5.3.2 China
5.3.3 South Korea
5.3.4 Japan
5.4 Rest of the World
5.4.1 Brazil
5.4.2 Middle East
5.4.3 Australia
6. Competitive Landscape
6.1 Introduction
6.2 Mergers & Acquisitions
6.3 Expansions
6.4 New Product Launch
6.5 Collaborations
7. COMPANY PROFILES
Abbott Laboratories
Alcon
Acucela
Ampio Pharma
Bausch and Lomb
Bristol-Myers Squibb
CIBA Vision
EyeGate Pharmaceuticals
Gene Signal
GSK
Johnson and Johnson
Merck & Co,Inc.
Novartis International,Inc.
Pfizer
Roche

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll